Key Takeaway
How to Prepare for Telehealth Weight Loss Appointment. Evidence-based answers from FormBlends, a physician-supervised telehealth weight loss clinic.
Here is what the current medical evidence says about how to prepare for telehealth weight loss appointment. At FormBlends, our physicians stay on top of the latest research to give patients clear, actionable information. Below we break down what you need to know, based on clinical data and our clinical experience.
What Does the Research Say About How to Prepare for Telehealth Weight Loss Appointment?
The medical literature on how to prepare for telehealth weight loss appointment provides several key findings:
- GLP-1 receptor agonists work by mimicking natural gut hormones that regulate appetite and blood sugar
- Clinical trials have shown consistent weight loss results across diverse patient populations
- Side effects are primarily gastrointestinal and tend to improve during the first weeks of treatment
- Physician supervision is important for monitoring progress and adjusting dosing
How Does This Apply to Your Treatment?
Knowing how to prepare for telehealth weight loss appointment matters because it directly affects treatment decisions. At FormBlends, our physicians consider this information when building your personalized protocol. Every patient is different, and what works for one person may need adjustment for another.
View data table
| Category | Search Volume Share (%) | Detail |
|---|---|---|
| Side Effects | 35 | Nausea, GI issues |
| Cost/Insurance | 28 | Pricing questions |
| Effectiveness | 22 | How much weight loss |
| Eligibility | 15 | BMI requirements |
We recommend discussing how to prepare for telehealth weight loss appointment with your FormBlends physician during your consultation. They can explain how it applies to your specific health history and weight loss goals.
Clinical Evidence for GLP-1 Weight Loss Medications
The STEP clinical trial program demonstrated semaglutide's effectiveness across multiple studies. In STEP 1[1], participants achieved 14.9% average weight loss over 68 weeks compared to 2.4% with placebo. The SURMOUNT trials for tirzepatide showed even greater results, with 22.5% weight[3] reduction at the highest 15mg dose. Both medications work by activating GLP-1 receptors in the brain and gut, slowing gastric emptying and reducing appetite through the hypothalamic satiety centers.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Liraglutide, the first FDA-approved GLP-1 for weight management since 2014, produces 8% average weight loss in clinical trials. The SCALE Obesity[2] and Prediabetes study showed 63.2% of participants lost at least 5% of their body weight on liraglutide[2] 3.0mg daily. Common side effects include nausea (39-44% of patients), diarrhea (20-30%), and vomiting (15-24%), typically resolving within 4-8 weeks of treatment initiation.
Clinical Evidence
The STEP 1 trial enrolled 1,961 adults[1] with obesity and demonstrated 14.9% average weight loss with semaglutide versus 2.4% placebo. SURMOUNT-1[3] showed tirzepatide achieved 22.5% weight[3] reduction at 15mg dose, establishing GLP-1 medications as the most effective non-surgical weight loss treatments available.
What Should You Do Next?
If you have questions about how to prepare for telehealth weight loss appointment, FormBlends can help. Our licensed physicians provide personalized guidance based on your medical history and goals. Start with a free online evaluation to connect with a provider who can answer your specific questions.
- Semaglutide for weight loss
- Tirzepatide for weight loss
- Compounded GLP-1 medications
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
Get Personalized Answers
General information is a starting point, but your treatment should be tailored to you. FormBlends connects you with licensed physicians who can evaluate your situation and provide specific recommendations. Complete your free evaluation today.